NasdaqGS:MLYSBiotechs
Is Mineralys Therapeutics’ (MLYS) New Shelf Registration Reframing Its Hypertension Bet Or Just Adding Flexibility?
In February 2026, Mineralys Therapeutics filed a US$113.58 million shelf registration for 4,076,827 common shares tied to an employee stock plan, while its Phase 3 Launch-HTN trial of lorundrostat was highlighted by JAMA and the company advanced preparations for a New Drug Application.
Together, the shelf registration and high-profile clinical recognition underscore how Mineralys is simultaneously strengthening its capital flexibility and the profile of its lead hypertension candidate.
We’ll...